Morgan Stanley Raises KYMR Price Target to $146
Key Points
- Morgan Stanley raised its price target on Kymera Therapeutics, Inc. to $146 from $135, maintaining an Overweight rating on the stock.
- Morgan Stanley's $146 price target implies 24.12% upside from Kymera Therapeutics, Inc.'s ($KYMR) current $117.62 share price.
- Kymera Therapeutics shares recently traded around $117.62, which is about equal to the closing price on the same day.
- The average target price for Kymera Therapeutics among analysts is $139.83, with a consensus rating of Strong Buy.
Get Kymera Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $KYMR.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Kymera Therapeutics, Inc. alert may contain errors. Disclosures
On October 27, 2026, Morgan Stanley raised its price target on Kymera Therapeutics, Inc. (KYMR) to $146 from $135, while maintaining an Overweight rating. This move reflects the firm's updated outlook on the company's growth potential. The information comes from Morgan Stanley's research note on the same date.
KYMR
Kymera Therapeutics, Inc.
Morgan Stanley vs. the S&P 500
Hypothetical returns from Morgan Stanley's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Kymera Therapeutics
Baker Bros. Advisors, LP holds 8,657,242 shares of Kymera, valued at about $1.02 billion, unchanged since June 30, 2026. Avoro Capital Advisors LLC also maintained its position with 7,474,747 shares worth around $879.2 million. BVF Inc. reduced its stake by 1,630,367 shares, now holding 3,872,052 shares valued at $455.5 million, a decrease of 29.6%. Siren, L.L.C. sold 251,133 shares, bringing its total to 2,935,830 shares worth about $345.3 million, down 7.9%.
Kymera Therapeutics, Inc. Stock Up 2.4%
Kymera Therapeutics shares recently traded around $117.62, which is about equal to the closing price on October 27, 2026. The stock is currently above its 50-day moving average by 2.3% and well above its 52-week low of $55.66. However, it remains below its 52-week high of $130.05, indicating potential for upward movement.
$KYMR price target
Kymera Therapeutics, Inc. daily closes and this analyst's $146 target. Not advice.
Recent Earnings
Kymera Therapeutics reported trailing twelve-month revenue of $105 million, with a year-over-year revenue growth of 466.4%. The company is scheduled to announce its next earnings on October 29, 2026, which may provide further insights into its financial performance.
Insider Buying and Selling at Kymera Therapeutics, Inc.
Insider activity includes Chief Executive Officer Nello Mainolfi, who sold 30,000 shares on October 1, 2026, valued at approximately $3.41 million. Earlier, he sold 50,000 shares on July 7, 2026, for about $5.95 million. Another insider, Brian R. Adams, sold 6,371 shares on September 4, 2026, valued at roughly $744,297. These sales occurred before the current rating and target change.
Analysts Set New Price Targets
On October 27, 2026, Morgan Stanley raised its price target on Kymera Therapeutics to $146 while maintaining its Overweight rating. Other analysts have also maintained their targets, with B of A Securities setting a target of $144, Stifel at $152, and Citigroup at $150, all in previous reports.
About Kymera Therapeutics
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, MA. It focuses on developing small molecule therapies that target and degrade disease-causing proteins using the body's natural systems. The recent analyst target raise reflects confidence in its innovative approach to treating various diseases.
Bottom Line
Investors should watch for Kymera Therapeutics' upcoming earnings report on October 29, 2026, as it may provide more insights into the company's financial health and growth trajectory. Morgan Stanley's recent target raise is part of a broader trend among analysts showing strong confidence in the stock's future performance.
Related Filing Alerts
Source: Morgan Stanley's rating change on $KYMR (Oct 27, 2026). Written by software, not financial advice. How we make alerts